ArticleWorld journal of microbiology & biotechnology2026
Effects of repeated culture in sub-inhibitory concentrations of ciprofloxacin on resistance and genetic characteristics of an ocular Pseudomonas aeruginosa isolate.
Article in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo analyse the resistance and genetic changes of a sensitive ocular isolate of Pseudomonas aeruginosa to repeated exposure to subinhibitory concentrations of ciprofloxacin.
methodsA ciprofloxacin-sensitive ocular isolate P. aeruginosa PA123 was serially passaged under gradually increasing sub-inhibitory concentrations of ciprofloxacin for 18 passages. The minimum inhibitory concentration (MIC) was determined daily using the broth microdilution method, and after 18 passages when resistance had plateaued, ciprofloxacin was withdrawn and passaging continued for a further 13 days. A control culture in the absence of ciprofloxacin was passaged sequentially for 31 days. Genomic DNA from selected passages was extracted and subjected to whole-genome sequencing. Sequencing reads were quality-trimmed using Trimmomatic 0.38 and then analysed with Snippy 4.6.0 to identify acquired mutations using parent PA123 (non-passaged) as a reference strain.
resultsThe parent strain had an initial MIC of 1 µg/mL, this increased during growth in sub-MIC ciprofloxacin two-fold at passage 4 (2 µg/mL), then progressively increased to 64 µg/mL at passage 15, at which it remained for a further three passages. Upon removal of ciprofloxacin, there was no change of the MIC (64 µg/mL) during the subsequent 13 passages. In early passages (P1-P7), PA123 acquired a Leu240 frameshift mutation in mexS, while in intermediate and later passages, Thr83Ile, Ala51Val, Asp87Tyr, duplication of alanine at position 570 (Ala570dup) mutations occurred in gyrA gene. Isolates from control passages acquired only background mutations unrelated to ciprofloxacin resistance.
conclusionStepwise accumulation of mutations in mexS and gyrA under sub-inhibitory ciprofloxacin pressure might lead to high-level resistance in PA123, with MICs remaining elevated even after drug removal, demonstrating stable resistance and linking sub-MIC exposure to resistance evolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.